Articles related to Avila Therapeutics

Avila Therapeutics: Exquisite targeting, compelling chemistry

October 21, 2009 - Conference: - Company:

With a platform to design and develop covalent drugs that have the depth and breadth to treat viral infections, cancers and autoimmune diseases, Avila Therapeutics in just three years has attracted USD 51 million in financing, and in July announced an option agreement with Novartis valued at USD 200 million in upfront payments and milestones. Read more »

Panel: Anatomy of a USD 200 million option deal

October 20, 2009 - Conference: - Company:

In July, 2009, Avila and Novartis entered into an option agreement on Avila’s advancement of a novel covalent drug program that included upfront and milestones payments to Avila, as well as an equity investment.

A rare opportunity to examine the details of a landmark deal by questioning partners on both sides of the negotiating table presents itself at BIO-Europe 2009 during a panel discussion Monday, November 2 at 1:00 pm. Read more »

Read more »

Newsletter

Subscribe to partneringNEWS
An online journal for executives in the life sciences, partneringNEWS™ is focused on the people behind the deals. Putting a human face to a collaboration agreement gives business development professionals the ability to get behind the headlines.

Sign up today to the free newsletter and never miss any new content.